Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.
Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
To learn more visit www.werewolftx.com.
Investor Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
